Clinical trial
The Safety and Efficacy of YTS109 Cell Injection for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy.
NCT06770504 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Efficacy of YTS109 Cell Injection for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy.
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- January 16, 2025
- Completion date
- December 30, 2026
- Enrollment
- 7 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
anti-cd19 star t-cell therapy, autoimmune hemolytic anemia, failure ≥3 lines of therapies